Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 5, No 1 (2012) PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING Abstract  similar documents
M. V. Protsenko, N. I. Koroleva
"... results as a new instrument in pharmaceutical marketing lets marketing specialists know what information ..."
 
Vol 9, No 3 (2016) EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS Abstract  similar documents
N. Z. Musina, V. V. Omelyanovskiy, A. V. Krasheninnikova
"... to prove the economic benefits of new technologies, to assess the need for follow-up phases of clinical ..."
 
Vol 9, No 3 (2016) EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON Abstract  similar documents
V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, D. V. Frolov, E. A. Ponomarev, A. S. Maslakov
"... Objective. The aim was to perform an indirect comparisons of the effectiveness and safety of new ..."
 
Vol 12, No 2 (2019) New framework for the development of clinical guidelines in Russia Abstract  similar documents
D. V. Blinov, E. S. Akarachkova, A. S. Orlova, E. V. Kryukov, D. I. Korabelnikov
 
Vol 8, No 3 (2015) RESEARCH EXCELLENCE INDEX AS INSTRUMENT OF PERFORMANCE-ORIENTED BUDGETING Abstract  similar documents
O. V. Bogacheva, V. E. Grigorov
"... . At the same time, several countries (Great Britain, Australia, New Zealand, et.al.) have accumulated vast ..."
 
Vol 8, No 1 (2015) PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION Abstract  similar documents
L. S. Melnikova
"... � Оплата новых дорогостоящих технологий в здравоохранении на основе соглашений по разделению ..."
 
Vol 7, No 1 (2014) ROLE OF RANDOMIZED TRIALS IN PHARMACOEPIDEMIOLOGY Abstract  similar documents
T. L. Galankin, A. S. Kolbin
"... Abstract: pharmacoepidemiology has recently evolved into a self-dependent post-marketing ..."
 
Vol 12, No 2 (2019) Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available Abstract  similar documents
F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev
"... Since generics and biosimilars have entered the Russian market of medications, there are new ..."
 
Vol 5, No 1 (2012) UN MILLENNIUM DEVELOPMENT GOALS INDICATORS ON PROBLEMS OF ACCESS TO ESSENTIAL MEDICINES AND ENHANCEMENT OF LOCAL PHARMACEUTICAL PRODUCER IN DEVELOPING COUNTRIES Abstract  similar documents
A. Y. Kulikov, A. G. Voskanyan
"... В статье рассматриваются ключевые вопросы развития локального фармацевтического производства и ..."
 
Vol 5, No 2 (2012) MEDICO-ECONOMIC SUBSTANTIATION OF NORMATIVE STANDARD OF SUPPLYING STUDENTS OF MILITARY SCHOOLS WITH MEDICATIONS Abstract  similar documents
Yu. V. Miroshnichenko, V. S. Gaynov
"... the study presents a characteristic of new normative act prepared by the Russian Federation ..."
 
Vol 9, No 1 (2016) PROSPECTS FOR THE USE OF METHODS OF ECONOMIC EVALUATION AT THE STAGE OF PLANNING AND ORGANISATION OF CLINICAL TRIALS Abstract  similar documents
N. Z. Musina, V. V. Tarasov
"... The article describes a new approach to the use of economic evaluation at the stage of planning ..."
 
Vol 7, No 1 (2014) EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE Abstract  similar documents
M. N. Kostyleva, Yu. B. Belousov, A. N. Gratsianskaya, S. S. Postnikov
"... ), account and analysis of the adverse reactions of drugs in post-marketing period are described. The off ..."
 
Vol 5, No 2 (2012) WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM Abstract  similar documents
A. I. Borodin
"... исследование опыта работы фирмы, занимающейся фармацевтическим бизнесом, подтвердило необходимость ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID Abstract  similar documents
K. V. Danilova, I. M. Razdorskaya
"... особенности фармацевтического рынка интраназальных глюкокортикостероидов города Липецка. ..."
 
Vol 7, No 1 (2014) CLINICAL AND ECONOMIC ANALYSIS IN ASSESSMENT OF HEALTH CARE TECHNOLOGIES IN HEALTH CARE INSTITUTIONS Abstract  similar documents
I. B. Gaykovaya, A. T. Burbello, A. I. Ermakov, A. S. Fedorenko, T. V. Vavilova, M. V. Komok
"... the introduction of new methods of clinical and laboratory diagnostics to assess the efficacy of drug therapy ..."
 
Vol 7, No 1 (2014) PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE Abstract  similar documents
S. A. Rachina, R. S. Kozlov, Yu. A. Belkova
"... demonstrated significant influence on public health, due to new findings in efficacy and safety, broadening ..."
 
Vol 9, No 4 (2016) PROPOSALS AND RECOMMENDATIONS FOR OPTIMIZATION OF THE PROGRAM OF STATE GUARANTEES FОR FREE MEDICAL CARE FOR RUSSIAN CITIZENS Abstract  similar documents
D. V. Fedyaev, D. V. Lukyantseva, V. I. Ignatyeva
"... approaches are aimed at the formation of a new system of documentary maintenance of the health system ..."
 
Vol 6, No 4 (2013) Using indirect comparisons in pharmacoeconomic examination Abstract  similar documents
Yu. E. Balykina, A. S. Kolbin
"... is the data of clinical studies. The experts are interested in not only the effect of a new medical technology ..."
 
Vol 10, No 3 (2017) Review of the current approaches to the assessment of the drug innovative potential worldwide Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits
"... significance of a new medical product and make an educated decision on the reimbursement, cost and priority ..."
 
Vol 6, No 2 (2013) HTA CORE MODEL Abstract  similar documents
R. I. Yagudina, T. Yu. Nor, A. D. Sevostyanov
"... be used for new technologies assessment wherever the program is applicable. HTA Core Model is based ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION Abstract  similar documents
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina
"... of simulation showed that the application of ART allows to significantly reduce new HIV infections and deaths ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... ) new practice where lenvatinib is used in 6.25% patients. Costs of drugs, visits to oncologist ..."
 
Vol 12, No 2 (2019) Recent changes in the pharmacovigilance system in the Russian Federation and the EAEU Abstract  similar documents
G. N. Gildeeva, A. V. Belostotsky
"... is required for any new medication (New Chemical Entity), including a new combination of drugs. The present ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... ), in Australia and new Zealand. The CeT is commonly used to rationalize decision-making in health cost ..."
 
Vol 10, No 3 (2017) Decision modelling for the evaluation of diabetes outcomes Abstract  similar documents
A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin
"... , empagliflozin) capable of significantly reducing cardiovascular risks in DM patients, require new approaches ..."
 
Vol 9, No 1 (2016) REVIEW OF HEALTH SYSTEM ORGANIZATION APPROACHES TO ESTIMATING SERVICE LEVELS AND EXPENDITURES FOR INPATIENT CARE SERVICES Abstract  similar documents
K. V. Gerasimova, D. V. Fedyaev, M. V. Sura, A. A. Tikhonova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... фармацевтического рынка, оценка эффективности медицинских технологий и снижение объемов оказываемой стационарной ..."
 
Vol 9, No 3 (2016) MONITORING OF CONSUMER ATTITUDES TO MEDICINES Abstract  similar documents
N. B. Dremova, N. P. Yaroshenko, N. I. Afanaseva, S. V. Solomka
"... этих качеств характеризуют фармацевтические особенности и семь – являются товароведческими параметрами ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... and panitumumab), and relatively new drug — regorafenib, which could be used for all patients. The aim ..."
 
Vol 6, No 3 (2013) METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES Abstract  similar documents
R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze
"... of utility researches are conducted using standard gamble method which is considered the classic instrument ..."
 
Vol 9, No 1 (2016) MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 Abstract  similar documents
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
"... body, chief Ministry of Health expert and the final committee decision. Results. 43 new drugs were ..."
 
Vol 12, No 1 (2019) Efficacy of photodynamic therapy in treatment of adult patients with skin cancer Abstract  similar documents
O. V. Kirsanova
"... Photodynamic therapy (PDT) is a relatively new non-surgical treatment for cancer and precancerous ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... Annually, all over the world there are 300 000 new patients with leukemia (approximately 3% of all ..."
 
Vol 9, No 2 (2016) GENDER FEATURES OF THE POPULATION'S ATTITUDE TO MEDICINES Abstract  similar documents
N. B. Dremova, N. P. Yaroshenko, N. I. Afanaseva, S. V. Solomka
"... десятилетия с изменением условий экономики в фармацевтическом секторе здравоохранения произошли значи ..."
 
Vol 11, No 1 (2018) Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) Abstract  similar documents
O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov
"... inevitably leads  to the development of new resistant strains. According to the published reports ..."
 
Vol 9, No 4 (2016) FACTORS AND EFFECTS OF PRIVATE HEALTH SPENDING Abstract  similar documents
O. A. Zarubina, N. N. Sisigina
"... on the national policy objectives, selected regulatory instruments as well as general socio-economic conditions ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... , выработать механизмы государственного стимулирования фармацевтических компаний снижать цены на орфанные ..."
 
Vol 11, No 3 (2018) Economic barriers restraining the production of therapeutic recombinant human trypsin. Use of innovative technologies to overcome them Abstract  similar documents
S. V. Ponomarenko
"... technology for its production, the marketing aspects and the prospective of enzyme therapy are addressed ..."
 
Vol 9, No 3 (2016) Мониторинг потребительского отношения населения к лекарственным средствам Abstract  similar documents
"... качеств лекарственных средств, среди которых 6 характеризуют их фармацевтические особенности и 7 являются ..."
 
Vol 10, No 4 (2017) THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE Abstract  similar documents
Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva
"... indicates the need for changes to produce new standards that would consider the “completed treatment” factor ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
"... . The comprehensive assessment of new technologies will provide for the transparency of the proposed system. ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... (EMA) [45]. В EC признание продукта орфанным дает фармацевтическим компаниям различные преференции ..."
 
Vol 9, No 3 (2016) Эффективность и безопасность пероральных антикоагулянтов при венозных тромбоэмболических осложнениях: непрямые сравнения Abstract  similar documents
"... Цель: Сравнительный анализ эффективности и безопасности новых пероральных антикоагулянтов ..."
 
Vol 8, No 2 (2015) PRINCIPLES OF IMPORT SUBSTITUTION REGARDING DRUGS Abstract  similar documents
Alana Viktorovna Dzaneva, Vitalii Vladimirovich Omel'yanovskii, Saniyat Aleksandrovna Kagermazova
"... организация «Фонд развития Центра разработки и коммерциализации новых технологий», Москва Резюме Данная ..."
 
Vol 7, No 4 (2014) АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS Abstract  similar documents
P. S. Nosova, O. V. Reshetko
"... фармацевтическом рынке принципиально новой группы антипсихотиков, атипичных нейролептиков, позволило значительно ..."
 
Vol 7, No 4 (2014) APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES Abstract  similar documents
V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova
"... закупать в первую очередь? В условиях появления новых медицинских технологий и совершенствования ..."
 
Vol 6, No 1 (2013) VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» Abstract  similar documents
"... новых комбинированных вакцин в календари профилактиче- ских прививок различных стран. Методы ..."
 
Vol 12, No 2 (2019) Concerning the “repression” of ω -3 polyunsaturated fatty acids by adepts of evidence-based medicine Abstract  similar documents
I. Yu. Torshin, O. A. Gromova, Zh. D. Kobalava
"... описаний отдельных исследований, во-вторых, учет важнейших характеристик фармацевтических различных форм ω ..."
 
Vol 5, No 2 (2012) VI Конгресс с международным участием «Развитие фармакоэкономики и фармакоэпидемиологии в Российской Федерации» Abstract  similar documents
"... перспективы их дальнейшего использования. Биосимиляры: новое понятие на отечественном фармацевтическом рынке ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... � Оплата новых дорогостоящих технологий в здравоохранении на основе соглашений по разделению ..."
 
1 - 50 of 137 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)